WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET). A live webcast will be available in the Investors & Media se ...

Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for congenital HI REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today shared observations from the Phase 3 sunRIZE study in patients ...

丽珠集团（000513）(000513.SZ)公告，公司控股子公司珠海市丽珠单抗生物技术有限公司("丽珠单抗") 与北京鑫康合生物医药科技有限公司联合开发的产品莱康奇塔单抗注射液于2025年12月26日被国家药品 监督管理局药品审评中心纳入拟优先审评品种公示名单;现公示期满后，根据国家药品监督管理局药品 审评中心网站信息公开显示，已纳入优先审评品种名单，正式进入药品上市许可优先审评审批程序。 ...

U.S. stock futures were mixed on Wednesday after a higher close on Tuesday. Futures of major benchmark indices were mixed.Investors are bracing for a heavy slate of economic releases, including the ADP employment report and ISM services index, on Wednesday.This follows the momentum that drove the Dow Jones roughly 1% higher to fresh record peaks during Tuesday’s rotation into blue-chip names. Meanwhile, the 10-year Treasury bond yielded 4.15%, and the two-year bond was at 3.46%. The CME Group's FedWatch too ...

First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases Evolution of Nucleome's non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need OXFORD, England, 07 January 2026 /PRNewswire/ -- Nucleome Therapeutics ('Nucleome' or 'the Company'), a company tackling the molecular causes of inflammatory diseases through a breakthrough approach to 3D human genetics, provides a ...

公司近期动态 - 公司管理层将参加一系列医学与投资者会议 包括1x1s around J P Morgan Healthcare Conference 2026年1月12日至14日 美国旧金山 UBS European Healthcare Conference 2026年3月3日至4日 英国伦敦 World Congress of Nephrology 2026年3月28日至31日 日本横滨 [1] - 公司为临床阶段生物技术公司 专注于开发治疗肾脏炎症和纤维化疾病的小分子药物 [2] - 公司最先进的研发项目是varoglutamstat 一种首创的口服QPCT L抑制剂 正在评估用于治疗糖尿病肾病 [2] 公司业务与战略 - 公司致力于通过调节病理相关蛋白的活性和稳定性来改变严重疾病的进程 以改善患者预后 [2] - 公司业务涉及炎症和纤维化疾病领域 主要聚焦于肾脏疾病 [2]

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce†and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF†) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate†or the "Company†) releases its total number of shares outstanding as well as its voting rights as of December 31, 2025: Total number of shares outstanding: 93,719,323 ordinary shares ...

Ventyx Biosciences Inc. (NASDAQ:VTYX) shares are trending on Wednesday. Check out the current price of VTVX stock here. Shares of the biopharma company jumped 62.59% to $16.34 in after-hours trading on Tuesday, following reports that Indianapolis-based Eli Lilly & Co. (NYSE:LLY) is in advanced talks to acquire the company for more than $1 billion, according to The Wall Street Journal.The report, citing sources, said a deal could be announced imminently.Ventyx and Eli Lilly did not immediately respond to Ben ...

涉及的公司与行业 * 公司：BeOne Medicines (ONC/688235.SS) [1] * 行业：全球肿瘤学/制药行业，专注于血液肿瘤和实体瘤治疗 [7] 核心观点与论据 * **Sonrotoclax在中国获批**：中国NMPA于1月5日批准了sonrotoclax用于治疗R/R CLL/SLL和R/R MCL（经CD20/BTKi治疗后），这是该药物在全球范围内的首次批准 [1] * **审批速度超常**：中国NDA审评仅用时八个月，快于通常的新药审批时间（12-18个月），反映了中国对BCL2抑制剂存在显著的未满足需求 [1] * **药物差异化优势**：新BCL2抑制剂（sonrotoclax和lisaftoclax）旨在提供比venetoclax更好的安全性，表现为更低的中性粒细胞减少症和停药率，且sonrotoclax的比率低于lisaftoclax [2][9] * **剂量爬坡更快**：lisaftoclax采用4-6天每日剂量爬坡方案，而sonrotoclax/venetoclax为每周爬坡 [2] * **中国BCL2市场特殊性**：分析师认为中国BCL2市场不能很好地代表全球格局，原因包括venetoclax在中国获批适应症有限导致BCL2渗透率低，以及lisaftoclax未在中国以外获批 [2] * **关注市场反馈**：分析师将关注venetoclax和lisaftoclax的销售增长情况，以及医生/患者对两种新BCL2抑制剂的反馈，特别是其差异化设计对市场的颠覆潜力 [2] * **盈利预测与目标价调整**：调整FY2025-2027E每股收益（从US$3.78/US$6.26/US$6.64调整至US$3.59/US$4.65/US$4.46），以反映：1) sonro在中国获批R/R MCL和CLL，混合成功概率从76%提升至95%；2) 微调近期sonro销售预测并增加SG&A投入；3) 微调近期Brukinsa销售预测；4) 因多个管线资产进入概念验证阶段而增加近期研发支出 [6] * **维持买入评级**：维持对ONC/A股(688235.SS)的买入评级，并将12个月目标价更新为ONC US$385.79（原US$408.79），A股为人民币345.86元（原人民币366.48元）[6] * **公司定位与优势**：BeOne Medicines是一家总部位于瑞士的全球肿瘤公司，拥有由Brukinsa和Tevimbra引领的血液肿瘤和实体瘤产品组合，在变革性业务合作、商业销售和研发方面有良好记录，在中国和美国拥有强大且差异化的商业特许经营权 [7] * **长期成本与时间优势**：公司拥有不断壮大的内部临床开发团队，长期来看，与同行相比具有额外的成本节约和产品上市时间优势 [7] * **估值方法**：目标价基于风险调整后的DCF估值（贴现率10%，永续增长率3%）以及63%的A股溢价（基于12个月平均值）[10] 其他重要内容 * **关键风险**：1) 研发/监管审批的不确定性，特别是相对早期的实体瘤领域；2) BTK/PD-1竞争；3) 临床阶段资产的开发风险；4) 市场准入瓶颈 [7][10] * **投资银行关系披露**：高盛在过去12个月内从BeOne Medicines Ltd. (A) 和 (ADR) 获得投资银行服务报酬（分别为人民币300.89元和320.30美元），并预计在未来3个月内寻求或获得相关报酬 [19] * **分析师认证**：报告中的观点准确反映了分析师个人观点，且其薪酬与报告中的具体建议或观点无直接或间接关联 [12] * **免责声明**：报告包含一般性信息，不构成个人投资建议，投资者应独立判断并考虑自身情况 [47]

Key Points The bull case wasn't helped by an analyst's recommendation downgrade. That pundit now feels the biotech's shares only rate a hold. 10 stocks we like better than Madrigal Pharmaceuticals › The New Year's Champagne turned flat for Madrigal Pharmaceuticals (NASDAQ: MDGL) on Tuesday. Investors traded out of the commercial-stage biotech following an analyst's recommendation downgrade. This resulted in the stock's price eroding by more than 5% that trading session. A high bar The prognostic ...